The objective of this study was a comparative investigation of the influence of concomitant food intake on the bioavailability of two nifedipine-containing controlled-release formulations. Adalat OROS and CORAL were compared in a randomised, non-blind, four-way crossover design in 24 healthy, male subjects after single dose administration following a high fat American breakfast or an overnight fast of 12 h, respectively. Plasma samples were withdrawn until 48 h post-dose. In the fasted state, the bioavailability (AUC and C(max) values) was lower for CORAL than for Adalat OROS. Under fed conditions, differences in bioavailability between both products were markedly increased. With respect to the therapeutic use of both products, the most important finding was the significant dose-dumping effect observed after fed administration of CORAL, resulting in nifedipine plasma concentrations of nearly three- to four-fold in 11 of 24 volunteers. The mean ratio of C(max) was 235% comparing CORAL with Adalat OROS under these conditions. The formulation-dependent food interaction observed in this study may be therapeutically relevant, especially in the case of changing administration conditions or switching from one product to the other.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0928-0987(02)00008-8DOI Listing

Publication Analysis

Top Keywords

adalat oros
12
formulation-dependent food
8
coral adalat
8
food effects
4
effects demonstrated
4
demonstrated nifedipine
4
nifedipine modified-release
4
modified-release preparations
4
preparations marketed
4
marketed european
4

Similar Publications

Melts of Octaacetyl Sucrose as Oral-Modified Release Dosage Forms for Delivery of Poorly Soluble Compound in Stable Amorphous Form.

AAPS PharmSciTech

February 2018

Institute of Technology, Faculty of Mathematics, Physics and Technical Science, Pedagogical University of Cracow, ul. Podchorążych 2, 30-084, Kraków, Poland.

The presented work describes the formulation and characterization of modified release glassy solid dosage forms (GSDFs) containing an amorphous nifedipine, as a model BCS (Biopharmaceutical Classification System) class II drug. The GSDFs were prepared by melting nifedipine together with octaacetyl sucrose. Dissolution profiles, measured under standard and biorelevant conditions, were compared to those obtained from commercially available formulations containing nifedipine such as modified release (MR) tablets and osmotic release oral system (OROS).

View Article and Find Full Text PDF

Background: Achieving the maximum reduction in cardiovascular morbidity and mortality is the primary goal of blood pressure (BP) control. Current guidelines recommend several antihypertensive classes as first-line therapy for this purpose but the decision on which agent/s to use will likely be based upon the treating physician's clinical experience. Observational studies provide a useful way of ascertaining the efficacy and tolerability of an antihypertensive in a real-life clinical setting.

View Article and Find Full Text PDF

Comparison of dissolution profiles obtained from nifedipine extended release once a day products using different dissolution test apparatuses.

Eur J Pharm Sci

September 2009

Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Friedrich-Ludwig-Jahn-Strasse 17, 17487 Greifswald, Germany.

Article Synopsis
  • The study examined new testing methods designed to better replicate the conditions of the gastrointestinal tract for dissolution testing of various extended release nifedipine formulations.
  • Four nifedipine formulations were analyzed using both traditional apparatus and two new testing devices, with results showing that dissolution characteristics were highly influenced by the testing conditions.
  • The findings suggest that mechanical robustness, along with pH dependency, plays a crucial role in the dissolution behavior of hydrogel matrix formulations.
View Article and Find Full Text PDF

Background: The osmotic-controlled release oral delivery system, OROS, is an advanced drug delivery technology that uses osmotic pressure as the driving force to deliver pharmacotherapy, usually once-daily, in several therapeutic areas.

Objective: The purpose of this review is to discuss the evolution of OROS technology and examine the many therapeutic areas where OROS products are being used.

Methods: A search of Medline and EMBASE were performed using the keywords 'OROS' and 'osmotic delivery' for the period January 1990 to June 2005.

View Article and Find Full Text PDF

The objective of this study was to compare the rate and extent of nifedipine bioavailability after single dose administration of Adalat OROS 30 (Reference) and Nifedipine Sandoz retard 30 tablets (Test). Both modified release formulations are marketed in Member States of the European Union. Prior to the clinical study the in vitro dissolution characteristics were investigated.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!